Edition:
India

OncoSec Medical Presents Interim Data From Ongoing Keynote-890 Study Evaluating Tavo In Combination With Keytruda


Friday, 13 Dec 2019 

Dec 13 (Reuters) - OncoSec Medical Inc ::ONCOSEC MEDICAL - PRESENTS INTERIM DATA FROM ONGOING KEYNOTE-890 STUDY EVALUATING TAVO IN COMBINATION WITH KEYTRUDA.ONCOSEC MEDICAL - TAVO, PEMBROLIZUMAB WERE WELL TOLERATED; ONLY 3 OF 16 PATIENTS EXPERIENCED GRADE 3 TREATMENT-RELATED ADVERSE EVENTS WITH TREATMENT.ONCOSEC MEDICAL - 4 OF 14 PATIENTS SHOWED RAPID TUMOR REDUCTION & HAD CONFIRMED PARTIAL RESPONSE BY RECIST V1.1.ONCOSEC MEDICAL INC - ONCOSEC EXPECTS TO REPORT FULL DATA RESULTS IN 2020 FROM KEYNOTE-890.